The sutureless aortic valve at 1 year: A large multicenter cohort study

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology
• Biomaterials in Medical Devices

Background:

• Sutureless aortic valve replacement (AVR) presents a promising alternative to conventional AVR for patients with aortic stenosis.
• The Perceval bovine pericardial valve is designed for sutureless implantation, potentially reducing procedure time and complications.

Purpose of the Study:

• To evaluate the safety and effectiveness of the Perceval sutureless AVR at one year in an intermediate-risk patient cohort.
• To assess clinical outcomes, including mortality, stroke, reoperation, and valve-related complications.

Main Methods:

• A prospective, single-arm study involving 658 intermediate-risk patients undergoing sutureless AVR with the Perceval valve.
• Data collected from 25 European centers between February 2010 and September 2013.
• Included assessment of mortality, stroke, reoperation, endocarditis, paravalvular leak, and echocardiographic parameters at one year.

Main Results:

• Low one-year event rates: 8.1% all-cause mortality, 4.5% cardiac mortality, 3.0% stroke, 1.9% reoperation, 1.4% endocarditis, and 0.6% major paravalvular leak.
• Significant improvement in New York Heart Association class (≥1 level in 77.5%) and stable functional status (70.4% NYHA class I/II at 1 year).
• Favorable hemodynamic profile with a mean effective orifice area of 1.5 cm² and mean gradient of 9.2 mm Hg; significant reduction in left ventricular mass.

Conclusions:

• The Perceval sutureless valve demonstrates favorable safety and efficacy profiles at one year in intermediate-risk patients undergoing AVR.
• The valve is associated with significant clinical improvement and low rates of major adverse events.
• These findings support the use of the Perceval sutureless valve in this patient population.